What is the clinical evidence from this study?

Study design: Cohort. Population: Extracranial oligometastatic disease (n=259). Intervention: Stereotactic body radiotherapy (SBRT). Primary outcome: Overall survival.

What question did this study set out to answer?

This study aims to evaluate the effectiveness of SBRT in achieving local control and improving survival outcomes for patients with extracranial oligometastatic disease.

June 20, 2026Clinical & Translational Oncology

The role of SBRT as an ablative treatment in oligometastatic patients

Q: What does this research mean for the field?

Stereotactic body radiotherapy (SBRT) achieves durable local control exceeding 80% beyond 4 years and a median overall survival of 93.8 months in patients with extracranial oligometastatic disease. Novelty: ClaimNovelty.CONFIRMATORY. Consensus alignment: ConsensusAlignment.SUPPORTS_CONSENSUS.

View Full Paper

Ask AI

Bookmark

Key result

SBRT linked to ~94 months median overall survival in extracranial oligometastatic disease.

n=259

Why the study?

Extracranial oligometastatic disease has potential for long-term control, and this study aimed to report institutional outcomes of SBRT across various oligometastatic scenarios.

Does SBRT provide durable local control and overall survival in patients with extracranial oligometastatic disease?

Population

259 patients with 401 extracranial oligometastatic lesions from solid tumors

Comparison

SBRT across oligometastatic scenarios

Design

Retrospective single-center study

Follow-up

Median of 68.7 months

Authors

BMBeatriz Debén MéndezHospital Universitario La Paz MRMarta Rodríguez-RoldánHospital Universitario La Paz MBMaria Isabel Garrido BotellaHospital Universitario Quirónsalud Madrid

Discussion

Member takes

Implication

May support SBRT for local control in select metastases; hypothesis-generating and leaves randomized survival confirmation open.

Key Points

This study aims to evaluate the effectiveness of SBRT in achieving local control and improving survival outcomes for patients with extracranial oligometastatic disease.
Retrospective analysis of 259 patients with 401 oligometastatic lesions treated with SBRT from 2016 to 2022.
Patients classified based on ESTRO–EORTC criteria and followed up using the Kaplan–Meier method for survival outcomes.
Inclusion criteria: ECOG 0–1, life expectancy > 6 months, ≤ 5 treatment-naïve metastases, no intracranial disease.
Durable local control achieved exceeding 80% beyond 4 years in all metastatic sites.
Median overall survival (OS) was 93.8 months (95% CI 81.1–106.4), with best outcomes in locoregional disease and prostate cancer.
Progression-free survival at 6 years was over 40%, highlighting efficacy in oligometastatic treatment.

Study Design

Type

Cohort (n=259)

Multicenter

Structured PICO

Does SBRT provide durable local control and overall survival in patients with extracranial oligometastatic disease?

Population

259 patients with 401 extracranial oligometastatic lesions from solid tumors, followed for a median of 68.7 months.

Exposure

Stereotactic body radiotherapy (SBRT)

Outcome

Local control and overall survival (OS)hard clinical

SBRT provides durable local control and prolonged overall survival in carefully selected patients with extracranial oligometastatic disease.

Limitations

Retrospective design
Single-center experience

Cite This Study

Méndez et al. (2026) conducted a cohort in Extracranial oligometastatic disease (n=259). Stereotactic body radiotherapy (SBRT) was evaluated on Overall survival. Stereotactic body radiotherapy achieved durable local control exceeding 80% beyond 4 years and a median overall survival of 93.8 months in patients with extracranial oligometastatic disease.

synapsesocial.com/papers/6a3722ab01fe431c251889bb https://doi.org/10.1007/s12094-026-04462-x

View Full Paper

Ask AI

Bookmark

The role of SBRT as an ablative treatment in oligometastatic patients

Discussion

Member takes

Implication

Key Points

Study Design

Structured PICO

Limitations

Cite This Study

The role of SBRT as an ablative treatment in oligometastatic patients

Discussion

Member takes

Implication

Key Points

Study Design

Structured PICO

Limitations

Cite This Study

Also Consider

Also Consider